Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficiency of CD19-PD1-CART in Relapsed/Refractory B Cell Lymphoma
NCT04163302Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD1-CD19-CART in B cell lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of Treatment-related Adverse Events at 3 years. Status: unknown.
02
Drugs
PD1-CD19-CART
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04163302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163302.